Women, men, and undergoing DBS surgery for Parkinson's
A recent study confirmed columnist Mollie Lombardi's observations about the different ways women and men approach DBS surgery for Parkinson's.| Parkinson's News Today
A recent study confirmed columnist Mollie Lombardi's observations about the different ways women and men approach DBS surgery for Parkinson's.| Parkinson's News Today
People with Parkinson's can have trouble identifying emotions, an idea that has columnist Mary Beth Skylis looking at her father anew.| Parkinson's News Today
Metabolic syndrome is associated with an increased risk of dementia among people with Parkinson's disease, according to a study from Turkey.| Parkinson's News Today
The FDA has cleared CAP-003, a gene therapy for Parkinson’s associated with GBA mutations, to be tested in clinical trials.| Parkinson's News Today
Cure Parkinson’s is funding SLEIPNIR, a clinical trial platform that will simultaneously test up to three disease-modifying treatments.| Parkinson's News Today
Sleep disorders were mainly associated with Parkinson's motor symptoms and problems regulating involuntary bodily functions, a s tudy shows.| Parkinson's News Today
In a trial, once-daily buntanetap halted cognitive decline in early-stage Parkinson's and improved cognition in patients with mild dementia.| Parkinson's News Today
No description.| Parkinson's News Today
Category archive page for News.| Parkinson's News Today
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto...| Parkinson's News Today
The American Parkinson Disease Association (APDA) has awarded $2.6 million to research projects aiming to better understand Parkinson's.| Parkinson's News Today
A history of upper gastrointestinal mucosal damage was associated with a 76% greater risk of subsequently developing Parkinson's disease.| Parkinson's News Today
The clinical trial is assessing the safety of Allyx Therapeutics' ALX-001 versus a placebo when given to adults twice daily for 28 days.| Parkinson's News Today
